相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel?
Antonio Gnoni et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2015)
Preoperative serum liver enzyme markers for predicting early recurrence after curative resection of hepatocellular carcinoma
Zhong-Xia Wang et al.
HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL (2015)
Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: Implications for clinical management
Michela Del Prete et al.
ONCOTARGET (2015)
The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib
Luca Faloppi et al.
ONCOTARGET (2015)
Basal and bevacizumb-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: a multicentric retrospective analysis
Nicola Silvestris et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2015)
Correlation between LDH levels and response to sorafenib in HCC patients: an analysis of the ITA.LI.CA database
Rodolfo Sacco et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS (2015)
The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management
Luca Faloppi et al.
BMC CANCER (2014)
VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: The ALICE-1 study
Mario Scartozzi et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
The role of Micro-RNAs in Hepatocellular Carcinoma: From Molecular Biology to Treatment
Marco D'Anzeo et al.
MOLECULES (2014)
Natural History of Malignant Bone Disease in Hepatocellular Carcinoma: Final Results of a Multicenter Bone Metastasis Survey
Daniele Santini et al.
PLOS ONE (2014)
Expression and prognostic value of VEGFR-2, PDGFR-β, and c-Met in advanced hepatocellular carcinoma
Jie Sheng Chu et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2013)
Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients
M. Scartozzi et al.
BRITISH JOURNAL OF CANCER (2012)
Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma
Josep M. Llovet et al.
CLINICAL CANCER RESEARCH (2012)
The Role of LDH Serum Levels in Predicting Global Outcome in HCC Patients Undergoing TACE: Implications for Clinical Management
Mario Scartozzi et al.
PLOS ONE (2012)
Prognostic relevance of oncological serum biomarkers in liver cancer patients undergoing transarterial chemoembolization therapy
Nikolaus Kohles et al.
TUMOR BIOLOGY (2012)
Hepatocelluar nodules in liver cirrhosis: hemodynamic evaluation (angiography-assisted CT) with special reference to multi-step hepatocarcinogenesis
Osamu Matsui et al.
ABDOMINAL IMAGING (2011)
Evolving strategies for the treatment of hepatocellular carcinoma: From clinical-guided to molecularly-taylored therapeutic options
Luca Faloppi et al.
CANCER TREATMENT REVIEWS (2011)
Prognostic and Predictive Role of Lactate Dehydrogenase 5 Expression in Colorectal Cancer Patients Treated with PTK787/ZK 222584 (Vatalanib) Antiangiogenic Therapy
Michael I. Koukourakis et al.
CLINICAL CANCER RESEARCH (2011)
Randomized, Placebo-Controlled, Phase III Study of Oxaliplatin, Fluorouracil, and Leucovorin With or Without PTK787/ZK 222584 in Patients With Previously Treated Metastatic Colorectal Adenocarcinoma
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Randomized, Placebo-Controlled, Phase III Study of First-Line Oxaliplatin-Based Chemotherapy Plus PTK787/ZK 222584, an Oral Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Metastatic Colorectal Adenocarcinoma
J. Randolph Hecht et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Inhibition of lactic dehydrogenase as a way to increase the anti-proliferative effect of multi-targeted kinase inhibitors
Luigi Fiume et al.
PHARMACOLOGICAL RESEARCH (2011)
Trans-arterial chemo-embolization (TACE), with either lipiodol (traditional TACE) or drug-eluting microspheres (precision TACE, pTACE) in the treatment of hepatocellular carcinoma: efficacy and safety results from a large mono-institutional analysis
Mario Scartozzi et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2010)
Serological diagnostic factors for liver metastasis in patients with colorectal cancer
Xiong-Zhi Wu et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2010)
Angiogenesis: From Chronic Liver Inflammation to Hepatocellular Carcinoma
Paloma Sanz-Cameno et al.
JOURNAL OF ONCOLOGY (2010)
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
Ann-Lii Cheng et al.
LANCET ONCOLOGY (2009)
Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma
Robert C. Kane et al.
ONCOLOGIST (2009)
Lactate dehydrogenase-5 (LDH-5) expression in human gastric cancer:: Association with hypoxia-inducible factor (HIF-1α) pathway, angiogenic factors production and poor prognosis
Yanislav Kolev et al.
ANNALS OF SURGICAL ONCOLOGY (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Global cancer statistics, 2002
DM Parkin et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2005)
Predictors and patterns of recurrence after resection of hepatocellular carcinoma
C Cha et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2003)
Factors predictive of 5-year survival after transarterial chemoembolization for inoperable hepatocellular carcinoma
CB O'Suilleabhain et al.
BRITISH JOURNAL OF SURGERY (2003)
Signal transduction to hypoxia-inducible factor 1
GL Semenza
BIOCHEMICAL PHARMACOLOGY (2002)
Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma
CM Lo et al.
HEPATOLOGY (2002)
分享论文
